Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas’ Izervay Accepted for Review in China for AMD
Astellas Pharma said on May 15 that Chinese regulatory authorities have accepted its new drug application for review for the complement C5 inhibitor Izervay (avacincaptad pegol).The company is seeking approval for the treatment of geographic atrophy secondary to age-related macular…
To read the full story
BUSINESS
- Regenxbio Appeals FDA CRL for MPS II Gene Therapy RGX-121
May 18, 2026
- Fuji Sees New Bio-AG Pricing Rules as Tailwind for Biosimilars
May 18, 2026
- Astellas’ Izervay Accepted for Review in China for AMD
May 18, 2026
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…